



Letter to the Editor

Cristina Borralleras¹
Javier Castrodeza Sanz²
Pilar Arrazola³
Carmen Cámara-Hijón⁴
José María Eiros⁵
María Fernández Prada⁶
Ángel Gil de Miguel⁷
Gloria Mirada⁸
Fernando Moraga-Llop⁹
Daniel Ocaña Rodríguez¹⁰
Joan Puig-Barberà¹¹
Jorge Vázquez¹²
Júlia Vergara-Alert¹³
Salomé de Cambra¹⁴

Update on Bimervax[®] immunogenicity amplitude. Insights on humoral response against XBB.1.5 from an extension study (NCT05142553)

¹Medical Information, HIPRA Human Health, Spain
²Area de Medicina Preventiva y Salud Pública. Facultad de Medicina y Hospital Clínico Universitario de Valladolid, Spain
³Servicio de Medicina Preventiva, Hospital Universitario 12 de Octubre, Madrid, Spain
⁴Servicio de Inmunología, Hospital Universitario La Paz, Madrid, Spain
⁵Area de Microbiología. Facultad de Medicina y Hospital Universitario "Río Hortega". Valladolid, Spain
⁶Servicio de Medicina Preventiva y Salud Pública. Hospital Vital Álvarez Buylla, Asturias, Spain
⁷Medicina Preventiva y Salud Pública. Director del Departamento de Especialidades Médicas y Salud, Spain
⁸Facultad de Enfermería y Fisioterapia, Universitat de Lleida (UdL), Spain
⁹Pediatra, Barcelona, Spain
¹⁰Family Medicine. Health Care Center Norte, Algeciras, Spain
¹¹Investigador Sénior Emérito. Area de Investigación en Vacunas, FISABIO, Valencia, Spain
¹²Director of Health Area, VINCES (Spain)
¹³Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CRESA), Campus de la Universitat Autònoma de Barcelona, Bellaterra Spain
¹⁴Medical Et Government Affairs. HIPRA Human Health, Spain

Article history

Received: 21 July 2023; Accepted: 28 August 2023; Published: 8 September 2023

Sir,

The World Health Organization (WHO) [1], in May 2023, and the European Medicines Agency (EMA) [2], in June 2023, published their recommendations on the composition of COVID-19 vaccines for the 2023-24 season. These recommendations, published after the acceptance of the manuscript, oblige the authors to produce a brief update and reinforce the Bimervax[®] vaccine positioning based on new evidence from the pivotal clinical trial (HIPRA-HH-2 extension, NCT05142553).

In 2023, COVID-19 cases have been mainly associated with the BQ and XBB.1.5 lineage variants, causing mostly mild cases, albeit also boosting hybrid immunity throughout the population. In early 2023, the XBB subvariant emerged and became predominant during the first semester of the year, accounting for around 90% of all variants in the winter period. Although in June XBB.1.5 still represented 75% of prevalent circulating sublineages, XBB.1.16 and XBB.2.3 appear to have been replacing it since April 2023.

The WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) postulates that new COVID-19 vaccine formulations should seek to induce antibody responses that neutralize XBB Omicron descendent lineages [1]. One recommended approach is the use of a monovalent XBB.1 descendent lineage, such as XBB.1.5, as the vaccine antigen, although other formulations and/or platforms that achieve ro-

bust neutralizing antibody responses against XBB descendent lineages can be considered [1]. They also recommend moving away from the inclusion of the index virus in future COVID-19 vaccine formulations [1]. The EMA's Emergency Task Force recommends updating vaccines to target XBB strains, which have become dominant in Europe and other parts of the world [2]. The EMA and ECDC have also noted that monovalent vaccines (vaccines targeting a single strain, such as XBB.1.5) are a reasonable choice for providing protection against current dominant and emerging strains [2].

The HIPRA-HH-2 extension trial started in September 2022 (vaccination period up until December 2022), and data from 288 individuals vaccinated with a fourth dose of Bimervax[®] (PHH-1V) up until May 30, 2023, have been collected, coinciding with the period of maximum prevalence of the BQ and XBB.1.5 subvariants. On the cut-off date, only 34 (11.8%) individuals reported COVID-19, and no cases of severe disease, hospitalizations or death due to COVID-19 were recorded. Neutralizing antibody titers against XBB.1.5 were analyzed 14 days after the booster in all participants and at 3 months in individuals reporting mild infection during the study period.

The preliminary results (Figure 1; Table 1) show that a fourth dose of PHH-1V elicited a significant neutralizing antibody response against XBB.1.5 14 days after the booster (GMT= 284.32, GMFR=5.45). Compared to the humoral response induced by PHH-1V vaccination against previous variants [3], the XBB.1.5 neutralizing antibody levels are lower, which is in line with the results obtained with boosters with other vaccines against the XBB.1.5 subvariant [4-6]. However, in the same extension study, natural infection with the virus

Correspondence:
Salomé de Cambra Florensa
HIPRA Human Health, Spain
Phone: +34 972 430 660
E-mail: salome.decambra@hipra.com




Figure 1 Geometric mean titer (GMT) of neutralizing antibodies against XBB.1.5 subvariant at baseline (blue bar) and day 14 (orange bar) after a boost with PHH-1V or after mild infection (red bar).

HIPRA-HH-2 extension study (NCT05142553)			
	GMT at baseline (95% CI)	GMT at day 14 (95% CI)	GMFR (95% CI)
Study population (N=190)	52.18 (38.305, 71.078)	284.32 (208.685, 387.376)	5.45 (4.51, 6.58)
GMT at 3 months (95% CI)			
Infected during study period (N=22)	500.11 (322.973, 774.386)		

CI: confidence interval

was also seen to elicit low XBB.1.5 neutralizing antibody levels (GMT=500.11, Figure 1; Table 1). In conclusion, both the Bimervax® vaccine (PHH-1V) and natural infection elicit a more discrete response compared to other variants, although considering the low percentage of individuals reporting infection (all mild), the response appears to be sufficient for protection from severe disease.

With the aforementioned results, this panel agrees on

the capacity of PHH-1V booster immunization to induce a broad humoral response against emerging variants, including the 2023 circulating subvariants (XBB.1.5), as well as to provide protection from severe disease. Future strains for the 2023-2024 are not currently foreseeable, although based on the existing evidence on current and incoming vaccines, the HIPRA PHH-1V is still a robust option for COVID-19 vaccination boosting.

REFERENCES

1. World Health Organization Statement on the antigen composition of COVID-19 vaccines. May 18th 2023. <https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines>
2. ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2. June 7th 2023. <https://www.ecdc.europa.eu/en/news-events/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants>
3. Corominas J, Garriga C, Prenafeta A, Moros A, Cañete M, Barreiro A, et al. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. *Lancet Reg Health Eur.* 2023; 28:100613. doi: <https://doi.org/10.1016/j.lanepe.2023.100613>
4. Sutandhio S, Furukasa K, Kurahashi Y, Marini MI, Effendi GB, Hasegawa N, et al. Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population. *J Infect Public Health.* 2023;16(7):1064-1072. doi: 10.1016/j.jiph.2023.05.004.
5. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med.* 2023;29(2):344-347. doi: 10.1038/s41591-022-02162-x.
6. Devasundaram S, Terpos E, Rosati M, Ntanasios-Stathopoulos I, Bear J, Burns R, et al. XBB.1.5 neutralizing antibodies upon bivalent COVID-19 vaccination are similar to XBB but lower than BQ.1.1. *Am J Hematol.* 2023 May;98(5):E123-E126. doi:10.1002/ajh.26887.